|
Feature
|
B
|
W
|
A
|
W+A
|
LLQ (pg/mL)
|
ULQ (pg/mL)
|
|---|
|
ALCAM
|
0
|
100
|
0
|
100
|
991
|
145528
|
|
CD27
|
10
|
90
|
0
|
90
|
508
|
148468
|
|
CD30
|
53
|
47
|
0
|
47
|
2460
|
128280
|
|
CTACK
|
0
|
100
|
0
|
100
|
43
|
10691
|
|
Eot-3
|
37
|
63
|
0
|
63
|
130
|
28149
|
|
FGF-2
|
31
|
67
|
2
|
69
|
102
|
5814
|
|
FGF-4
|
57
|
43
|
0
|
43
|
260
|
14563
|
|
Follistatin
|
8
|
92
|
0
|
92
|
138
|
57120
|
|
GRO-g
|
12
|
75
|
13
|
88
|
59
|
4344
|
|
I-TAC
|
11
|
89
|
0
|
89
|
16
|
6191
|
|
ICAM-1
|
1
|
76
|
23
|
99
|
289
|
29018
|
|
IFN-g
|
39
|
60
|
1
|
61
|
14
|
7365
|
|
IFN-w
|
37
|
58
|
5
|
63
|
1177
|
42508
|
|
IGF-II
|
0
|
85
|
15
|
100
|
46
|
13538
|
|
IGF-1R
|
33
|
67
|
0
|
67
|
330
|
91601
|
|
IGFBP-1
|
2
|
72
|
26
|
98
|
272
|
85578
|
|
IGFBP-3
|
0
|
7
|
93
|
100
|
5530
|
30760
|
|
IGFBP-4
|
0
|
80
|
20
|
100
|
410
|
22880
|
|
IL-1 sR1
|
30
|
70
|
0
|
70
|
534
|
54857
|
|
IL-10rb
|
12
|
88
|
0
|
88
|
28
|
11331
|
|
IL-16
|
28
|
72
|
0
|
72
|
724
|
86874
|
|
IL-1 srII
|
19
|
81
|
0
|
81
|
509
|
76440
|
|
IL-2rb
|
71
|
29
|
0
|
29
|
10277
|
107828
|
|
LT bR
|
14
|
86
|
0
|
86
|
34
|
37957
|
|
Lymphotactin
|
28
|
72
|
0
|
72
|
166
|
9216
|
|
M-CSF R
|
0
|
91
|
9
|
100
|
1951
|
121318
|
|
MIP-3a
|
16
|
84
|
0
|
84
|
13
|
3389
|
|
MMP-10
|
10
|
90
|
0
|
90
|
158
|
42033
|
|
PDGF-Ra
|
30
|
66
|
5
|
70
|
8112
|
151722
|
|
PF4
|
0
|
23
|
77
|
100
|
67
|
5458
|
|
TGF-a
|
33
|
67
|
0
|
67
|
35
|
2678
|
|
TIMP-2
|
0
|
12
|
88
|
100
|
130
|
25224
|
|
TRAIL R1
|
33
|
67
|
0
|
67
|
21
|
10956
|
|
VAP-1
|
1
|
23
|
76
|
99
|
4624
|
150226
|
|
VE-cadherin
|
1
|
94
|
5
|
99
|
2652
|
146826
|
|
VEGF-D
|
34
|
66
|
0
|
66
|
1370
|
100539
|
|
b-NGF
|
27
|
73
|
0
|
73
|
141
|
12400
|
- Data shown is from titrations run in 8 client projects (1000 clinical samples surveyed) covering 8 diverse disease areas. The percentage of samples falling below (B), within (W) or above (A) the linear range of detection are presented. The analyte was considered to be detectable if the W+A percentage was above 50%.
